N
Novo Nordisk
Global healthcare company developing medicines and delivery systems for serious chronic diseases
About Novo Nordisk
Novo Nordisk is a Denmark-based healthcare company that discovers, develops and delivers biological medicines and related delivery systems. Founded in 1923 and headquartered in Bagsværd, the company focuses on serious chronic diseases, including diabetes, obesity, and rare blood and endocrine disorders. Its activities span pharmaceutical research and development, clinical development, manufacturing, and the distribution of approved medicines to healthcare systems and patients worldwide. The company also works with external partners and invests in production capacity and scientific capabilities to support access to its treatments.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1923
- Headquarters
- Gladsaxe Municipality, Denmark
- Listing
- IPO 1983
- Employees
- 62,059
- Open positions
- 174
- Dealroom signal
- 30.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Weight Management, Metabolism, AI Drug Discovery, Drug Development, Cardiology and cardiovascular, Horizon Europe, Diabetes, Personal Health
- Business model
- Manufacturing
- Client focus
- b2c
- Investment activity
- 32 companies, latest Dec 2025
- Capital deployed
- $966M
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Jun 2025 | $0 | — | Parvus Asset Management | ↗ |
| POST IPO EQUITY✓Other financing | Mar 2024 | $0 | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Novo Nordisk is 340K monthly website visits, up 9.7% over the last three months. Novo Nordisk's team declined 5.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 AstraZenecaBiopharmaceutical solutions for major global diseases |
Cambridge, United Kingdom | Operational | 76,461 | $2.1B | $290B |
 ABIONYXDeveloping of novel therapies for the treatment of cardiovascular and metabolic diseases |
Balma, France | Operational | |||
 SyndromeXDrugs for the Metabolic Syndrome and its diseases |
Jerusalem, Israel | Operational | |||
 BayerGlobal enterprise with core competencies in the Life Science fields of health care and agriculture |
Leverkusen, Germany | Operational | |||
 JanuaryProvides the tools and insights to take charge of one’s own health in a simple and actionable way |
Menlo Park, United States | Operational | |||
 RimidiRimidi- Serious Hope for Healthcare |
Atlanta, United States | Acquired | |||
 ValbiotisSolutions for cardio-metabolic diseases prevention |
Perigny, France | Operational | |||
 HumaProvides a digital health platform used for predictive care and research |
London, United Kingdom | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Akero TherapeuticsCambridge, United StatesInnovative therapies targeting metabolic liver disease
$5.2Bvaluation
Soufflé TherapeuticsWatertown, United StatesTargeted siRNA medicines for genetic and autoimmune diseases
$800Mvaluation
CantonitxLeiden, NetherlandsSmall molecule NNMT inhibitors for cardiometabolic diseases
→
Aspect BiosystemsVancouver, CanadaCommercializing cutting-edge bioprinting technologies
$460Mvaluation
Eikonizo TherapeuticsCambridge, United StatesDeveloping therapies to improve the treatment of human disease, specifically neurodegenerative diseases
$160Mvaluation
TT
Tanai TherapeuticsGhent, BelgiumOral therapeutics for obesity targeting energy expenditure
$14Mvaluation
Nine DiagnosticsCambridge, United StatesHolistic health profiles using nanoscale sensing for faster, effective treatment optimization
$320Kvaluation
Tanai TherapeuticsGhent, BelgiumDeveloping a new class of obesity treatments
→
Cardior PharmaceuticalsHanover, GermanyNon-coding RNA-based therapeutics in heart failure
$1.1Bvaluation
EraCal TherapeuticsSchlieren, SwitzerlandA biotech company developing first-in-class drugs to treat different diseases
$4Mvaluation
Embark BiotechCopenhagen, DenmarkNovel therapeutics for obesity and metabolic diseases
→
Inversago PharmaSt-Eustache, CanadaSpecialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists
$1.1Bvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later3 investors entered at this stage
- SMScuti Capital Management
Financial Architects- PMParvus Asset Management
Other known investors2 additional known investors
5AM Ventures
Innovate UK Business Connect
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Novo Nordisk on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Novo Nordisk’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.